Kura Oncology Inc（KURA）股票分析KURAKura Oncology Inc

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Kura Oncology Inc is a good buy right now, primarily driven by the CEO's recent $2.35 million stock purchase, which signals confidence in the company's future. Additionally, the stock has shown a robust 40.51% increase over the last 20 days and a current price of $12.66, well above the Fibonacci support level of $11.175. However, the main risk is the negative earnings trend, with a reported EPS of -0.77, indicating ongoing losses.

5 analysts cover KURA: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 29.71.